Skip to main content
SpringerLink
Log in

Enzyme replacement therapy and beyond—in memoriam Roscoe O. Brady, M.D. (1923–2016)

  • Review
  • Published:
Journal of Inherited Metabolic Disease

Abstract

Lysosomal storage disorders are strong candidates for the development of specific innovative therapies. The discovery of enzyme deficiencies is an important milestone in understanding the underlying cause of disease. Being able to replace the first missing enzyme in a lysosomal storage required three decades of dedicated research. Successful drug development for lysosomal storage disorders was fostered by the U.S. Orphan Drug Act. Various optimization strategies have the potential to overcome the current limitations of enzyme replacement therapies. In addition, substrate reduction therapies are an alternative approach to treat lysosomal storage disorders, chemical chaperones enhance residual enzyme activity, and small molecules can facilitate substrate transport through subcellular compartments. Bone-marrow derived multipotent stem cells and gene therapies have received FDA orphan drug designation status. The science of small clinical trials played an essential role: non-neurological endpoints, biomarker, and regulatory alignment are key factors in successful drug development for lysosomal storage disorders. Being able to treat brain disease is the next frontier. This review is dedicated to the memory of Roscoe O. Brady, an early pioneer in the research of lysosomal storage diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  • Aghion H (1934) La maladie de Gaucher dans l’enfance. In Editor ed.^eds. Book La maladie de Gaucher dans l’enfance Paris

  • Altarescu G, Hill S, Wiggs E et al (2001a) The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher’s disease. J Pediatr 138:539–547

    Article  CAS  PubMed  Google Scholar 

  • Altarescu GM, Goldfarb LG, Park KY et al (2001b) Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease. Clin Genet 60:46–51

    Article  CAS  PubMed  Google Scholar 

  • Anderson W (1898). A case of “angeiokeratoma”. Br J Dermatol 10:113–17

  • Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO (1990) Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci U S A 87:1913–1916

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Barton NW, Brady RO, Dambrosia JM et al (1991) Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med 324:1464–1470

    Article  CAS  PubMed  Google Scholar 

  • Baudhuin P, Hers HG, Loeb H (1964) An electron microscopic and biochemical study of type II glycogenosis. Lab Invest 13:1139–1152

    CAS  PubMed  Google Scholar 

  • Blanz J, Stroobants S, Lullmann-Rauch R et al (2008) Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice. Hum Mol Genet 17:3437–3445

    Article  CAS  PubMed  Google Scholar 

  • Boado RJ, Zhang Y, Zhang Y, Xia CF, Wang Y, Pardridge WM (2008) Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood–brain barrier. Biotechnol Bioeng 99:475–484

    Article  CAS  PubMed  Google Scholar 

  • Brady RO (1966) The sphingolipidoses. N Engl J Med 275:312–318

    Article  CAS  PubMed  Google Scholar 

  • Brady RO, Kanfer JN, Shapiro D (1965) Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher’s Disease. Biochem Biophys Res Commun 18:221–225

    Article  CAS  PubMed  Google Scholar 

  • Brady RO, Kanfer JN, Mock MB, Fredrickson DS (1966) The metabolism of sphingomyelin. II. evidence of an enzymatic deficiency in Niemann-Pick diseae. Proc Natl Acad Sci U S A 55:366–369

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry’s disease—ceramidetrihexosidase deficiency. N Engl J Med 276:1163–1167

    Article  CAS  PubMed  Google Scholar 

  • Brady RO, Tallman JF, Johnson WG et al (1973) Replacement therapy for inherited enzyme deficiency. use of purified ceramidetrihexosidase in Fabry’s disease. N Engl J Med 289:9–14

    Article  CAS  PubMed  Google Scholar 

  • Brady RO, Pentchev PG, Gal AE, Hibbert SR, Dekaban AS (1974) Replacement therapy for inherited enzyme deficiency. use of purified glucocerebrosidase in Gaucher’s disease. N Engl J Med 291:989–993

    Article  CAS  PubMed  Google Scholar 

  • Brady RO, Murray GJ, Barton NW (1994) Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease. J Inherit Metab Dis 17:510–519

    Article  CAS  PubMed  Google Scholar 

  • Branton MH, Schiffmann R, Sabnis SG et al (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine 81:122–138

    Article  CAS  PubMed  Google Scholar 

  • Calias P, Papisov M, Pan J et al (2012) CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder. PLoS One 7:e30341

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chen Y, Jin M, Goodrich L, Smith G, Coppola G, Calhoun DH (2000) Purification and characterization of human alpha-galactosidase A expressed in insect cells using a baculovirus vector. Protein Expr Purif 20:228–236

    Article  CAS  PubMed  Google Scholar 

  • Clarke JT, Mahuran DJ, Sathe S et al (2011) An open-label phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants). Mol Genet Metab 102:6–12

    Article  CAS  PubMed  Google Scholar 

  • Conzelmann E, Sandhoff K (1983) Partial enzyme deficiencies: residual activities and the development of neurological disorders. Dev Neurosci 6:58–71

    Article  PubMed  Google Scholar 

  • Cox T, Lachmann R, Hollak C et al (2000) Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet (London, England) 355:1481–1485

    Article  CAS  Google Scholar 

  • Cox TM, Drelichman G, Cravo R et al (2015) Eliglustat compared with imiglucerase in patients with Gaucher’s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet (London, England) 385:2355–2362

    Article  CAS  Google Scholar 

  • Crow JM (2016) Advocacy: strong foundations. Nature 537:S152–S154

    Article  CAS  PubMed  Google Scholar 

  • Davidson CD, Ali NF, Micsenyi MC et al (2009) Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One 4:e6951

    Article  PubMed  PubMed Central  Google Scholar 

  • De Duve C (1964) From cytases to lysosomes. Fed Proc 23:1045–1049

    Google Scholar 

  • Dohil R, Fidler M, Gangoiti JA, Kaskel F, Schneider JA, Barshop BA (2010) Twice-daily cysteamine bitartrate therapy for children with cystinosis. J Pediatr 156(71–75):e71–e73

    Article  Google Scholar 

  • Dunbar CE, Kohn DB, Schiffmann R et al (1998) Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum Gene Ther 9:2629–2640

    Article  CAS  PubMed  Google Scholar 

  • Eng CM, Guffon N, Wilcox WR et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry’s disease. N Engl J Med 345:9–16

    Article  CAS  PubMed  Google Scholar 

  • Fabry J (1898) Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). Arch Dermatol Syph 43:187–200

    Article  Google Scholar 

  • Fan JQ, Ishii S, Asano N, Suzuki Y (1999) Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 5:112–115

    Article  CAS  PubMed  Google Scholar 

  • FDA (2011) “Drug Approval Package Xarelto (Rivaroxaban) 10 mg immediate release tablets.” Retrieved 3 Sept 2015, from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022406Orig1s000TOC.cfm

  • FDA “Search Orphan Drug Designations and Approvals’ Retrieved 20 Dec 2013, from http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm

  • Felice BR, Wright TL, Boyd RB et al (2011) Safety evaluation of chronic intrathecal administration of idursulfase-IT in cynomolgus monkeys. Toxicol Pathol 39:879–892

    Article  CAS  PubMed  Google Scholar 

  • Ferla R, O’Malley T, Calcedo R et al (2013) Gene therapy for mucopolysaccharidosis type VI is effective in cats without pre-existing immunity to AAV8. Hum Gene Ther 24:163–169

    Article  CAS  PubMed  Google Scholar 

  • Fratantoni JC, Hall CW, Neufeld EF (1968a) The defect in Hurler’s and Hunter’s syndromes: faulty degradation of mucopolysaccharide. Proc Natl Acad Sci U S A 60:699–706

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fratantoni JC, Hall CW, Neufeld EF (1968b) Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 162:570–572

    Article  CAS  PubMed  Google Scholar 

  • Furbish FS, Blair HE, Shiloach J, Pentchev PG, Brady RO (1977) Enzyme replacement therapy in Gaucher’s disease: large-scale purification of glucocerebrosidase suitable for human administration. Proc Natl Acad Sci U S A 74:3560–3563

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gahl WA, Reed GF, Thoene JG et al (1987) Cysteamine therapy for children with nephropathic cystinosis. N Engl J Med 316:971–977

    Article  CAS  PubMed  Google Scholar 

  • Gaucher PCE (1882) De l’épithélioma primitif de la rate. Hypertrophie idiopathique de la rate sans leucémie. In Editor ed.^eds. Book De l’épithélioma primitif de la rate. Hypertrophie idiopathique de la rate sans leucémie: Paries

  • Germain DP, Giugliani R, Hughes DA et al (2012) Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies. Orphanet J Dis 7:91

    Article  Google Scholar 

  • Germain DP, Hughes DA, Nicholls K et al (2016) Treatment of Fabry’s disease with the pharmacologic chaperone migalastat. N Engl J Med 375:545–555

    Article  CAS  PubMed  Google Scholar 

  • Gershon RC, Cella D, Fox NA, Havlik RJ, Hendrie HC, Wagster MV (2010) Assessment of neurological and behavioural function: the NIH toolbox. Lancet Neurol 9:138–139

    Article  PubMed  Google Scholar 

  • Goker-Alpan O, Wiggs EA, Eblan MJ et al (2008) Cognitive outcome in treated patients with chronic neuronopathic Gaucher disease. J Pediatr 153:89–94

    Article  PubMed  Google Scholar 

  • Grabowski GA, Barton NW, Pastores G et al (1995) Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 122:33–39

    Article  CAS  PubMed  Google Scholar 

  • Gulmans VA, van Veldhoven NH, de Meer K, Helders PJ (1996) The six-minute walking test in children with cystic fibrosis: reliability and validity. Pediatr Pulmonol 22:85–89

    Article  CAS  PubMed  Google Scholar 

  • Haffner ME, Torrent-Farnell J, Maher PD (2008) Does orphan drug legislation really answer the needs of patients? Lancet (London, England) 371:2041–2044

    Article  Google Scholar 

  • Harmatz P, Whitley CB, Waber L et al (2004) Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 144:574–580

    Article  CAS  PubMed  Google Scholar 

  • Haurigot V, Marco S, Ribera A, et al (2013) Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Investig 123:3254–3271

  • Hollak CE, Aerts JM, Ayme S, Manuel J (2011) Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. Orphanet J Rare Dis 6:16

    Article  PubMed  PubMed Central  Google Scholar 

  • IQWiG (2005) Rapid-acting insulin analogues in children and adolescents with diabetes mellitus type 1 - follow-up commission. Executive summary of final report A08-01, Version 1.0. In Institute for quality and efficiency in health care: Executive Summaries Cologne, Germany

  • Jones SA, Breen C, Heap F et al (2016) A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA. Mol Genet Metab 118:198–205

    Article  CAS  PubMed  Google Scholar 

  • Kan SH, Troitskaya LA, Sinow CS et al (2014) Insulin-like growth factor II peptide fusion enables uptake and lysosomal delivery of alpha-N-acetylglucosaminidase to mucopolysaccharidosis type IIIB fibroblasts. Biochem J 458:281–289

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Khanna R, Flanagan JJ, Feng J et al (2012) The pharmacological chaperone AT2220 increases recombinant human acid alpha-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease. PLoS One 7:e40776

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kishnani PS, Corzo D, Nicolino M et al (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68:99–109

    Article  CAS  PubMed  Google Scholar 

  • Klenk E (1934) Über die Natur der Phosphatide der Milz bei Niemann-Pickscher Krankheit. Z Physiol Chem 229

  • Kolter T, Sandhoff K (2005) Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids. Annu Rev Cell Dev Biol 21:81–103

    Article  CAS  PubMed  Google Scholar 

  • Leavitt M, Rutkowski JV, Xu H, Canty D, Quinn AG (2013) Biochemical evidence of the effects of SBC-103, a recombinant human alpha-N-acetylglucosaminidase in a mucopolysaccharidosis IIIB mouse model using an improved analytical method for substrate quantification. Mol Genet Metab 108:S58–S59

    Article  Google Scholar 

  • Leinekugel P, Michel S, Conzelmann E, Sandhoff K (1992) Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet 88:513–523

    Article  CAS  PubMed  Google Scholar 

  • Lonser RR, Warren KE, Butman JA et al (2007) Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. technical note. J Neurosurg 107:190–197

    Article  PubMed  Google Scholar 

  • MacDonald IM, Noel LP, Mintsioulis G, Clarke WN (1990) The effect of topical cysteamine drops on reducing crystal formation within the cornea of patients affected by nephropathic cystinosis. J Pediatr Ophthalmol Strabismus 27:272–274

    CAS  PubMed  Google Scholar 

  • Maga JA, Zhou J, Kambampati R et al (2013) Glycosylation-independent lysosomal targeting of acid alpha-glucosidase enhances muscle glycogen clearance in pompe mice. J Biol Chem 288:1428–1438

    Article  CAS  PubMed  Google Scholar 

  • McDonald CM, Henricson EK, Han JJ et al (2010) The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 41:500–510

    Article  PubMed  Google Scholar 

  • Mechler K, Mountford WK, Hoffmann GF, Ries M (2015) Pressure for drug development in lysosomal storage disorders—a quantitative analysis thirty years beyond the US orphan drug act. Orphanet J Rare Dis 10:46

    Article  PubMed  PubMed Central  Google Scholar 

  • Mistry PK, Lukina E, Ben Turkia H et al (2015) Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. Jama 313:695–706

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Miyamoto S, Nagaya N, Satoh T et al (2000) Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161:487–492

    Article  CAS  PubMed  Google Scholar 

  • Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A (2007) A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab 90:329–337

    Article  CAS  PubMed  Google Scholar 

  • Muenzer J, Hendriksz CJ, Fan Z et al (2016) A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. Genet Med: Off J Am Coll Med Genet 18:73–81

    Article  CAS  Google Scholar 

  • Nan Z, Shekels L, Ryabinin O et al (2012) Intracerebroventricular transplantation of human bone marrow-derived multipotent progenitor cells in an immunodeficient mouse model of mucopolysaccharidosis type I (MPS-I). Cell Transplant 21:1577–1593

    Article  PubMed  Google Scholar 

  • NCBI (2017a) National Center for Biotechnology Information. PubChem Compound Database; CID=20057354, https://pubchem.ncbi.nlm.nih.gov/compound/20057354. Accessed 20 Jan 2017

  • NCBI (2017b) National Center for Biotechnology Information. PubChem Compound Database; CID=23652731, https://pubchem.ncbi.nlm.nih.gov/compound/23652731. Accessed 20 Jan 2017

  • NCBI (2017c) National Center for Biotechnology Information. PubChem Compound Database; CID=51634, https://pubchem.ncbi.nlm.nih.gov/compound/51634. Accessed 20 Jan 2017

  • Ohashi T (2012) Enzyme replacement therapy for lysosomal storage diseases. Pediatr Endocrinol Rev 10(Suppl 1):26–34

    PubMed  Google Scholar 

  • Ou L, Herzog T, Koniar BL, Gunther R, Whitley CB (2014) High-dose enzyme replacement therapy in murine Hurler syndrome. Mol Genet Metab 111:116–122

    Article  CAS  PubMed  Google Scholar 

  • PDBe (2017) Protein Data Bank in Europe 3gxi, author: Lieberman, RL. Crystal structure of acid-beta-glucosidase at pH 5.5, http://www.ebi.ac.uk/pdbe/entry/pdb/3gxi. Accessed 20 Jan 2017

  • Pentchev PG, Brady RO, Hibbert SR, Gal AE, Shapiro D (1973) Isolation and characterization of glucocerebrosidase from human placental tissue. J Biol Chem 248:5256–5261

    CAS  PubMed  Google Scholar 

  • Ries M, Gupta S, Moore DF et al (2005) Pediatric Fabry disease. Pediatrics 115:e344–e355

    Article  PubMed  Google Scholar 

  • Ries M, Clarke JT, Whybra C et al (2006a) Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 118:924–932

    Article  PubMed  Google Scholar 

  • Ries M, Moore DF, Robinson CJ et al (2006b) Quantitative dysmorphology assessment in Fabry disease. Genet Med: Off J Am Coll Med Genet 8:96–101

    Article  Google Scholar 

  • Ries M, Clarke JT, Whybra C et al (2007a) Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents. J Clin Pharmacol 47:1222–1230

    Article  CAS  PubMed  Google Scholar 

  • Ries M, Kim HJ, Zalewski CK et al (2007b) Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease. Brain: J Neurol 130:143–150

    Article  CAS  Google Scholar 

  • Sabatini DD, Adesnik MB (2005) The biogenesis of membranes and organelles, chap 16. McGraw-Hill, New York

  • Sandhoff K, Kolter T (2003) Biosynthesis and degradation of mammalian glycosphingolipids. Philos Trans R Soc Lond B Biol Sci 358:847–861

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schiffmann R, Ries M (2016) Fabry disease: a disorder of childhood onset. Pediatr Neurol 64:10–20

    Article  PubMed  Google Scholar 

  • Schiffmann R, Murray GJ, Treco D et al (2000) Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 97:365–370

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schiffmann R, Kopp JB, Austin HA 3rd et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. Jama 285:2743–2749

    Article  CAS  PubMed  Google Scholar 

  • Schiffmann R, Askari H, Timmons M et al (2007) Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol: JASN 18:1576–1583

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schiffmann R, Fitzgibbon EJ, Harris C et al (2008) Randomized, controlled trial of miglustat in Gaucher’s disease type 3. Ann Neurol 64:514-522

    Article  PubMed  PubMed Central  Google Scholar 

  • Schiffmann R, Swift C, Wang X, Blankenship D, Ries M (2015) A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease. J Inherit Metab Dis 38:1129-36

  • Schueler UH, Kolter T, Kaneski CR, Zirzow GC, Sandhoff K, Brady RO (2004) Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease. J Inherit Metab Dis 27:649–658

    Article  CAS  PubMed  Google Scholar 

  • Shah MR, Hasselblad V, Gheorghiade M et al (2001) Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. Am J Cardiol 88:987–993

    Article  CAS  PubMed  Google Scholar 

  • Sohn YB, Lee J, Cho SY et al (2013) Improvement of CNS defects via continuous intrathecal enzyme replacement by osmotic pump in mucopolysaccharidosis type II mice. Am J Med Genet A 161A:1036–1043

    Article  PubMed  Google Scholar 

  • Stockklausner C, Lampert A, Hoffmann GF, Ries M (2016) Novel treatments for rare cancers: The U.S. orphan drug act is delivering-a cross-sectional analysis. Oncologist 21:487–493

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Strothotte S, Strigl-Pill N, Grunert B et al (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257:91–97

    Article  CAS  PubMed  Google Scholar 

  • Sun B, Zhang H, Franco LM et al (2005) Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol Therapy: J Am Soc Gene Therapy 11:57–65

    Article  CAS  Google Scholar 

  • Sun Y, Liou B, Xu YH et al (2012) Ex vivo and in vivo effects of isofagomine on acid beta-glucosidase variants and substrate levels in Gaucher disease. J Biol Chem 287:4275–4287

    Article  CAS  PubMed  Google Scholar 

  • Svennerholm L (1962) The chemical structure of normal human brain and Tay-Sachs gangliosides. Biochem Biophys Res Commun 9:436–441

    Article  CAS  PubMed  Google Scholar 

  • Sweeley CC, Klionsky B (1963) Fabry’s disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid. J Biol Chem 238:3148–3150

    CAS  PubMed  Google Scholar 

  • Tay W (1881) Symmetrical changes in the region of the yellow spot in each eye of an infant. Trans Ophthalmol Soc 1:55–57

    Google Scholar 

  • Tenneze L, Daurat V, Tibi A, Chaumet-Riffaud P, Funck-Brentano C (1999) A study of the relative bioavailability of cysteamine hydrochloride, cysteamine bitartrate and phosphocysteamine in healthy adult male volunteers. Br J Clin Pharmacol 47:49–52

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tropak MB, Reid SP, Guiral M, Withers SG, Mahuran D (2004) Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients. J Biol Chem 279:13478–13487

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wraith JE, Clarke LA, Beck M et al (2004) Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 144:581–588

    Article  CAS  PubMed  Google Scholar 

  • Zhou Q, Stefano JE, Harrahy J et al (2011) Strategies for Neoglycan conjugation to human acid alpha-glucosidase. Bioconjug Chem 22:741–751

    Article  CAS  PubMed  Google Scholar 

  • Zimran A, Brill-Almon E, Chertkoff R et al (2011) Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 118:5767–5773

    Article  CAS  PubMed  Google Scholar 

  • Zimran A, Altarescu G, Elstein D (2013) Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells Mol Dis 50:134–137

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, Heidelberg University Hospital, Heidelberg, Germany

    Markus Ries

  2. Center for Rare Disorders, Heidelberg University Hospital, Im Neuenheimer Feld 430, D-69120, Heidelberg, Germany

    Markus Ries

Authors
  1. Markus Ries
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus Ries.

Additional information

Communicated by: Marc Patterson

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ries, M. Enzyme replacement therapy and beyond—in memoriam Roscoe O. Brady, M.D. (1923–2016). J Inherit Metab Dis 40, 343–356 (2017). https://doi.org/10.1007/s10545-017-0032-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10545-017-0032-8

Keywords

Search

Navigation